胃泌素抑制肽(GIP)重組蛋白
Recombinant Gastric Inhibitory Polypeptide (GIP)
Incretin hormone; Glucose Dependent Insulinotropic Peptide
- 編號RPA882Hu01
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來源原核表達
- 宿主E.coli
- 內毒素水平<1.0EU/µg(LAL法測定)
- 亞細胞定位分泌
- 預測分子量18.6kDa
- 實際分子量19kDa(差異分析請參閱說明書)
- 片段與標簽Glu22~Arg153 with N-terminal His Tag
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 90%
- 等電點7.9
-
應用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 840 ¥ 2100 ¥ 4200 ¥ 12600 ¥ 31500
- 欲了解實際交易價格和更多情況，請與當地經銷商聯系!
-
產品包裝(模擬)
-
產品包裝(模擬)
-
Figure. Gene Sequencing (Extract)
-
SDS-PAGE圖
-
通過ISO 9001、ISO 13485質量體系認證
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩定性
熱穩定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產生。保質期內，在適當的條件下存儲，損失率低于5%。
增值服務
相關產品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應用(僅供研究使用，不用于臨床診斷！) |
| RPA882Hu01 | 胃泌素抑制肽(GIP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| CPA882Hu11 | 胃泌素抑制肽(GIP)牛血清白蛋白偶聯物 | Immunogen; SDS-PAGE; WB. |
| CPA882Hu21 | 胃泌素抑制肽(GIP)卵白蛋白偶聯物 | Immunogen; SDS-PAGE; WB. |
| PAA882Hu08 | 胃泌素抑制肽(GIP)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA882Hu01 | 胃泌素抑制肽(GIP)多克隆抗體 | WB; IHC; ICC; IP. |
| MAA882Hu21 | 胃泌素抑制肽(GIP)單克隆抗體 | WB,IHC. |
| MAA882Hu22 | 胃泌素抑制肽(GIP)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA882Hu23 | 胃泌素抑制肽(GIP)單克隆抗體 | WB; IHC; ICC; IP. |
| CEA882Hu | 胃泌素抑制肽(GIP)檢測試劑盒(酶聯免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA882Hu | 胃泌素抑制肽(GIP)等多因子檢測試劑盒(流式熒光發光法) | FLIA Kit for Antigen Detection. |
| KSA882Hu11 | 胃泌素抑制肽(GIP)檢測試劑盒DIY材料(酶聯免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻
| 雜志 | 參考文獻 |
| Scientific Reports | The?anti-hyperglycemic?efficacy?of a?lipid-lowering?drug?Daming?capsule?and the?underlyingsignaling?mechanisms?in a?rat?model?of?diabetes?mellitus. [pubmed:27721485] |
| Obesity surgery | The Effects of Duodenojejunal Omega Switch in Combination with High-Fat Diet and Control Diet on Incretins, Body Weight, and Glucose Tolerance in Sprague-Dawley Rats. [pubmed:28840471] |
| Obesity?Surgery? | Preserving Duodenal-Jejunal (Foregut) Transit Does Not Impair Glucose Tolerance and Diabetes Remission Following Gastric Bypass in Type 2 Diabetes Sprague?… [Pubmed:29098544] |
| BioMed Research International | Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity [] |
| Diabetes Research and Clinical Practice | Low AS160 and high SGK basal phosphorylation associates with impaired incretin profile and type 2 diabetes in adipose tissue of obese patients [Pubmed: 31734225] |
| OBESITY SURGERY | The Leading Role of Peptide Tyrosine Tyrosine in Glycemic Control After Roux-en-Y Gastric Bypass in Rats [Pubmed: 31701411] |
| FUTURE SCIENCE | Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes [Pubmed:35251693] |
留言咨詢
